Get to know our clinical trials
Trial of iptacopan (LNP023) in C3 glomerulopathy or idiopathic membranoproliferative glomerulonephritis mediated by immunocomplexes.
THE PRIMARY PURPOSE OF THIS EXTENSION STUDY IS TO COLLECT LONGER-TERM EFFICACY, SAFETY AND TOLERABILITY DATA IN ELIGIBLE PARTICIPANTS RECEIVING OPEN-LABEL IPTACOPAN AFTER COMPLETION OF TREATMENT FROM THE PHASE 2, PROOF-OF-CONCEPT GC3 STUDY, CLNP023X2202.
Technical Summary
- OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF IPTACOPAN (LNP023) IN C3 GLOMERULOPATHY OR IDIOPATHIC IMMUNOCOMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
- Code EudraCT: 2023-509343-27
- Protocol number: CLNP023B12001B
- Promoter: Novartis Farmaceutica
- Molecule/Drug: Iptacopán (LNP023)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.